News & Updates

Show Multimedia Only

Tremelimumab plus durvalumab safe as first-line treatment for uHCC patients

17 Jan 2026 by

The use of single tremelimumab (T) regular interval durvalumab (D), or STRIDE, results in a manageable safety profile in Asian patients with unresectable hepatocellular carcinoma (uHCC), as shown by the preliminary results of the SIERRA study.

Tremelimumab plus durvalumab safe as first-line treatment for uHCC patients

17 Jan 2026

Simvastatin does little to prevent recurrence of pancreatitis

17 Jan 2026

Treatment with simvastatin does not appear to reduce the recurrence of pancreatitis when compared with placebo, according to interim data from a study.

Simvastatin does little to prevent recurrence of pancreatitis

17 Jan 2026

$Big survival gains in relapsed/refractory multiple myeloma seen with immunotherapy combo$

Big survival gains in relapsed/refractory multiple myeloma seen with immunotherapy combo

16 Jan 2026 by

For patients with multiple myeloma who have received up to three lines of therapy, combination treatment with the bispecific antibody teclistamab plus the monoclonal antibody daratumumab yields significant improvements in progression-free survival and overall survival, according to the phase III MajesTEC-3 trial.

Big survival gains in relapsed/refractory multiple myeloma seen with immunotherapy combo

16 Jan 2026

Odronextamab plus chemo safe as DLBCL treatment, with promising efficacy

16 Jan 2026 by

Combination treatment with the CD20×CD3 bispecific antibody odronextamab and chemotherapy is generally safe among previously untreated diffuse large B cell lymphoma (DLBCL) patients, without new safety signals, as shown by the results from part 1 of the phase III Olympia-3 study.

Odronextamab plus chemo safe as DLBCL treatment, with promising efficacy

16 Jan 2026

Oral anticoagulant therapy tied to risk of abnormal uterine bleeding

16 Jan 2026

Oral anticoagulant users, particularly young women, have an increased likelihood of abnormal uterine bleeding, according to a nested matched case–control study.

Oral anticoagulant therapy tied to risk of abnormal uterine bleeding

16 Jan 2026

EPIK-B5 supports alpelisib plus fulvestrant for HR+, HER2– ABC

15 Jan 2026 by

In the phase III EPIK-B5 study, adding alpelisib, an α-specific PI3K inhibitor, to fulvestrant improves progression-free survival (PFS) in men and postmenopausal women with HR+, HER2− advanced breast cancer (ABC) harbouring a PIK3CA mutation who have progressed on or after treatment with an aromatase inhibitor (AI) and a CDK4/6 inhibitor (CDK4/6i).

EPIK-B5 supports alpelisib plus fulvestrant for HR+, HER2– ABC

15 Jan 2026

Frontline anlotinib-containing regimen shows promise in advanced soft-tissue sarcoma

14 Jan 2026

In the treatment of patients with advanced soft-tissue sarcoma, combining anlotinib with anthracyclines and ifosfamide in the first-line setting followed by anlotinib maintenance has demonstrated promising efficacy, with acceptable toxicities, in a phase II study.

Frontline anlotinib-containing regimen shows promise in advanced soft-tissue sarcoma

14 Jan 2026

Novel syringe improves HCP experience during aspiration

14 Jan 2026 by

A novel syringe demonstrates better user experience than a hypodermic syringe during aspiration by standardizing the process, regardless of user, drug type, volume, or injection site, reports a study.

Novel syringe improves HCP experience during aspiration

14 Jan 2026

Z-drug exposure during early pregnancy not a risk factor for congenital malformations

14 Jan 2026

The use of nonbenzodiazepine sedative hypnotics (Z-drugs) for sleep dysregulation during the first trimester of pregnancy does not appear to contribute to a meaningful increase in the risk of congenital malformations overall, as shown in a study.

Z-drug exposure during early pregnancy not a risk factor for congenital malformations

14 Jan 2026

Omega-3 fatty acid supplementation does nothing for youths with depression

13 Jan 2026

In the treatment of children and adolescents with major depressive disorder (MDD), adjunctive supplementation with omega-3 fatty acid does not appear to significantly improve outcomes compared with placebo, according to study.

Omega-3 fatty acid supplementation does nothing for youths with depression

13 Jan 2026

News & Updates

Showing Pharmacy articles

Showing

Specialty:

Tremelimumab plus durvalumab safe as first-line treatment for uHCC patients

Tremelimumab plus durvalumab safe as first-line treatment for uHCC patients

Simvastatin does little to prevent recurrence of pancreatitis

Simvastatin does little to prevent recurrence of pancreatitis

Big survival gains in relapsed/refractory multiple myeloma seen with immunotherapy combo

Big survival gains in relapsed/refractory multiple myeloma seen with immunotherapy combo

Odronextamab plus chemo safe as DLBCL treatment, with promising efficacy

Odronextamab plus chemo safe as DLBCL treatment, with promising efficacy

Oral anticoagulant therapy tied to risk of abnormal uterine bleeding

Oral anticoagulant therapy tied to risk of abnormal uterine bleeding

EPIK-B5 supports alpelisib plus fulvestrant for HR+, HER2– ABC

EPIK-B5 supports alpelisib plus fulvestrant for HR+, HER2– ABC

Frontline anlotinib-containing regimen shows promise in advanced soft-tissue sarcoma

Frontline anlotinib-containing regimen shows promise in advanced soft-tissue sarcoma

Novel syringe improves HCP experience during aspiration

Novel syringe improves HCP experience during aspiration

Z-drug exposure during early pregnancy not a risk factor for congenital malformations

Z-drug exposure during early pregnancy not a risk factor for congenital malformations

Omega-3 fatty acid supplementation does nothing for youths with depression

Omega-3 fatty acid supplementation does nothing for youths with depression